Emesis (Vomiting) - Pipeline Review, H2 2012 - This report 'Emesis (Vomiting) - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Emesis (Vomiting), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Emesis (Vomiting). Emesis (Vomiting) - Pipeline Review, Half Year is built using data and information sourced from our proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Emesis (Vomiting).
- A review of the Emesis (Vomiting) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Emesis (Vomiting) pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Emesis (Vomiting).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Emesis (Vomiting) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Emesis (Vomiting) Overview
Therapeutics Development
An Overview of Pipeline Products for Emesis (Vomiting)
Emesis (Vomiting) Therapeutics under Development by Companies
Emesis (Vomiting) Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Emesis (Vomiting) Therapeutics – Products under Development by Companies
Emesis (Vomiting) Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Emesis (Vomiting) Therapeutics Development
ProStrakan Group plc
Helsinn Healthcare S.A.
Ikano Therapeutics, Inc.
Sparsha Pharma International Pvt. Ltd.
Emesis (Vomiting) – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Antiemetic - Drug Profile
Product Description
Mechanism of Action
R&D Progress
granisetron - Drug Profile
Product Description
Mechanism of Action
R&D Progress
dronabinol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ondansetron - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Palonosetron + Temozolomide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ondansetron - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Metoclopramide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
netupitant + palonosetron hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
aprepitant - Drug Profile
Product Description
Mechanism of Action
R&D Progress
5-HT3 Receptor Antagonist Patch - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PF0713 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Palonosetron + Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
granisetron - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Emesis (Vomiting) Therapeutics – Drug Profile Updates
Emesis (Vomiting) Therapeutics – Discontinued Products
Emesis (Vomiting) Therapeutics - Dormant Products
Emesis (Vomiting) – Product Development Milestones
Featured News & Press Releases
Apr 12, 2012: OPKO Health Initiates Phase III Clinical Trials Of Rolapitant For Prevention Of CINV
Apr 09, 2012: RedHill Biopharma Announces Positive Preliminary Results In Ondansetron Study
Feb 14, 2012: RedHill Biopharma To Commence Bioequivalence Study Of Ondansetron
Jan 04, 2012: Acacia Pharma Initiates Phase II Study With APD421 In Post-Operative Nausea & Vomiting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products Under Development for Emesis (Vomiting), H2 2012
Products under Development for Emesis (Vomiting) – Comparative Analysis, H2 2012
Number of Products under Development by Companies, H2 2012
Number of Products under Investigation by Universities/Institutes, H2 2012
Comparative Analysis by Late Stage Development, H2 2012
Comparative Analysis by Mid Clinical Stage Development, H2 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012
Products under Development by Companies, H2 2012
Products under Investigation by Universities/Institutes, H2 2012
ProStrakan Group plc, H2 2012
Helsinn Healthcare S.A., H2 2012
Ikano Therapeutics, Inc., H2 2012
Sparsha Pharma International Pvt. Ltd., H2 2012
Assessment by Monotherapy Products, H2 2012
Assessment by Combination Products, H2 2012
Assessment by Stage and Route of Administration, H2 2012
Assessment by Stage and Molecule Type, H2 2012
Emesis (Vomiting) Therapeutics – Drug Profile Updates
Emesis (Vomiting) Therapeutics – Discontinued Products
Emesis (Vomiting) Therapeutics – Dormant Products
List of Figures
Number of Products under Development for Emesis (Vomiting), H2 2012
Products under Development for Emesis (Vomiting) – Comparative Analysis, H2 2012
Products under Development by Companies, H2 2012
Products under Investigation by Universities/Institutes, H2 2012
Late Stage Products, H2 2012
Mid Clinical Stage Products, H2 2012
Discovery and Pre-Clinical Stage Products, H2 2012
Assessment by Monotherapy Products, H2 2012
Assessment by Combination Products, H2 2012
Assessment by Route of Administration, H2 2012
Assessment by Stage and Route of Administration, H2 2012
Assessment by Molecule Type, H2 2012
Assessment by Stage and Molecule Type, H2 2012 26
